P C Lunney1,2, V C Kariyawasam3, R R Wang1,4, K L Middleton1,3, T Huang5,6, C P Selinger3,7, J M Andrews8, P H Katelaris1,3, R W L Leong1,3,5. 1. Sydney Medical School, Concord Clinical School, Concord Repatriation General Hospital, The University of Sydney, Sydney, NSW, Australia. 2. Dubbo Base Hospital, Dubbo, NSW, Australia. 3. Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, NSW, Australia. 4. Royal North Shore Hospital, Sydney, NSW, Australia. 5. Faculty of Medicine, The University of New South Wales, Sydney, NSW, Australia. 6. St. George Hospital, Sydney, NSW, Australia. 7. Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 8. Department of Gastroenterology, Royal Adelaide Hospital, Adelaide, SA, Australia.
Abstract
BACKGROUND: Smoking demonstrates divergent effects in Crohn's disease (CD) and ulcerative colitis (UC). Smoking frequency is greater in CD and deleterious to its disease course. Conversely, UC is primarily a disease of nonsmokers and ex-smokers, with reports of disease amelioration in active smoking. AIM: To determine the prevalence of smoking and its effects on disease progression and surgery in a well-characterised cohort of inflammatory bowel diseases (IBD) patients. METHODS: Patients with smoking data of the Sydney IBD Cohort were included. Demographic, phenotypic, medical, surgical and hospitalisation data were analysed and reported on the basis of patient smoking status. RESULTS: 1203 IBD patients were identified comprising 626 CD and 557 UC with 6725 and 6672 patient-years of follow-up, respectively. CD patients were more likely to smoke than UC patients (19.2% vs. 10.2%, P < 0.001). A history of smoking in CD was associated with an increased proportional surgery rate (45.8% vs. 37.8%, P = 0.045), requirement for IBD-related hospitalisation (P = 0.009) and incidence of peripheral arthritis (29.8% vs. 22.0%, P = 0.027). Current smokers with UC demonstrated reduced corticosteroid utilisation (24.1% vs. 37.5%, P = 0.045), yet no reduction in the rates of colectomy (3.4% vs. 6.6%, P = 0.34) or hospital admission (P = 0.25) relative to nonsmokers. Ex-smokers with UC required proportionately greater immunosuppressive (36.2% vs. 26.3%, P = 0.041) and corticosteroid (43.7% vs. 34.5%, P = 0.078) therapies compared with current and never smokers. CONCLUSIONS: This study confirms the detrimental effects of smoking in CD, yet failed to demonstrate substantial benefit from smoking in UC. These data should encourage all patients with IBD to quit smoking.
BACKGROUND: Smoking demonstrates divergent effects in Crohn's disease (CD) and ulcerative colitis (UC). Smoking frequency is greater in CD and deleterious to its disease course. Conversely, UC is primarily a disease of nonsmokers and ex-smokers, with reports of disease amelioration in active smoking. AIM: To determine the prevalence of smoking and its effects on disease progression and surgery in a well-characterised cohort of inflammatory bowel diseases (IBD) patients. METHODS:Patients with smoking data of the Sydney IBD Cohort were included. Demographic, phenotypic, medical, surgical and hospitalisation data were analysed and reported on the basis of patient smoking status. RESULTS: 1203 IBD patients were identified comprising 626 CD and 557 UC with 6725 and 6672 patient-years of follow-up, respectively. CDpatients were more likely to smoke than UC patients (19.2% vs. 10.2%, P < 0.001). A history of smoking in CD was associated with an increased proportional surgery rate (45.8% vs. 37.8%, P = 0.045), requirement for IBD-related hospitalisation (P = 0.009) and incidence of peripheral arthritis (29.8% vs. 22.0%, P = 0.027). Current smokers with UC demonstrated reduced corticosteroid utilisation (24.1% vs. 37.5%, P = 0.045), yet no reduction in the rates of colectomy (3.4% vs. 6.6%, P = 0.34) or hospital admission (P = 0.25) relative to nonsmokers. Ex-smokers with UC required proportionately greater immunosuppressive (36.2% vs. 26.3%, P = 0.041) and corticosteroid (43.7% vs. 34.5%, P = 0.078) therapies compared with current and never smokers. CONCLUSIONS: This study confirms the detrimental effects of smoking in CD, yet failed to demonstrate substantial benefit from smoking in UC. These data should encourage all patients with IBD to quit smoking.
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Joseph Meserve; Satimai Aniwan; Jenna L Koliani-Pace; Preeti Shashi; Aaron Weiss; David Faleck; Adam Winters; Shreva Chablaney; Gursimran Kochhar; Brigid S Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; Justin G Hartke; Prianka Chilukuri; Matthew Bohm; Sashidhar Varma Sagi; Monika Fischer; Dana Lukin; David Hudesman; Shannon Chang; Youran Gao; Keith Sultan; Arun Swaminath; Nitin Gupta; Sunanda Kane; Edward V Loftus; Bo Shen; Bruce E Sands; Jean-Frederic Colombel; Corey A Siegel; William J Sandborn; Parambir S Dulai Journal: Clin Gastroenterol Hepatol Date: 2018-09-27 Impact factor: 11.382
Authors: Kimberly N Weaver; Michael D Kappelman; Robert S Sandler; Christopher F Martin; Wenli Chen; Kristen Anton; Millie D Long Journal: Inflamm Bowel Dis Date: 2016-11 Impact factor: 5.325